+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Klebsiella Pneumoniae Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • PDF Icon

    Report

  • 138 Pages
  • July 2022
  • Region: Global
  • Global Markets Direct
  • ID: 5645064
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Klebsiella pneumoniae Infections - Drugs In Development, 2022, provides an overview of the Klebsiella pneumoniae Infections (Infectious Disease) pipeline landscape.

Klebsiella pneumoniae is a Gram-negative bacteria. A Klebsiella pneumoniae infection is caused when the organism is able to enter the lungs. A Klebsiella pneumoniae infection is very common in patients with underlying diseases like diabetes, chronic lung diseases and chronic alcoholics. It is mostly a nosocomial infection that occurs in hospitalized patients with weakened immune system. Symptoms include necrosis, inflammation, hemorrhage, chills, dizziness, high fever, head ache and chest pain. Treatment includes antibiotics and hygiene lifestyle.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Klebsiella pneumoniae Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Klebsiella pneumoniae Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 1, 1, 42, 12 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 3 molecules, respectively.

Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Klebsiella pneumoniae Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Klebsiella pneumoniae Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Klebsiella pneumoniae Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Klebsiella pneumoniae Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Report Coverage
  • Klebsiella pneumoniae Infections - Overview
  • Klebsiella pneumoniae Infections - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Klebsiella pneumoniae Infections - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Klebsiella pneumoniae Infections - Companies Involved in Therapeutics Development
  • Klebsiella pneumoniae Infections - Drug Profiles
  • Klebsiella pneumoniae Infections - Dormant Projects
  • Klebsiella pneumoniae Infections - Discontinued Products
  • Klebsiella pneumoniae Infections - Product Development Milestones
  • Featured News & Press Releases
  • Jul 07, 2020: Data published in Ebiomedicine validates novel scientific approach that disarms bacterial defenses to treat or prevent life-threatening infections
  • Sep 05, 2019: Summit presented in vivo proof of concept data for targeted Enterobacteriaceae antibiotics at ASM/ESCMID Conference
  • Aug 27, 2019: Vaccine against deadly superbug Klebsiella effective in mice
  • Aug 20, 2019: Vaxxilon receives grant to develop new prophylactic vaccine
  • Jul 02, 2019: Appili Therapeutics signs $3M USD grant contract with the United States Department of Defense to develop antibiotics that target superbugs
  • Apr 03, 2019: Summit’s pipeline expands with series of new mechanism antibiotics targeting Enterobacteriaceae
  • May 07, 2018: Melinta Therapeutics Receives Up to $6.2 Million from CARB-X to Advance Clinical Development of a Novel Antimicrobial to Combat Antibiotic-Resistant Bacteria
  • Apr 17, 2018: Arsanis to Present Abstract On ASN300 At The 28th European Congress of Clinical Microbiology And Infectious Diseases
  • Nov 07, 2017: Appili Therapeutics Receives $1.2M USD from the Department of Defense to Advance Antibiotic Targeting Drug-Resistant Bacteria
  • Sep 30, 2017: Development of a negamycin analogue targeting the translational machinery in gram-negative drug-resistant pathogens for the treatment of Infections
  • Apr 20, 2017: Arsanis Presents Data on ASN-300 at the 27th European Congress of Clinical Microbiology and Infectious Diseases
  • Apr 11, 2017: Appili Therapeutics Receives Funding from the Government of Canada to Support Development of New Antibiotic To Treat Gram-Negative Infections
  • Jun 17, 2016: Arsanis Presents Data at ASM Microbe 2016 Demonstrating Protection Against Klebsiella pneumoniae using Monoclonal Antibody Technology
  • Mar 09, 2015: Phico Therapeutics Receives Translation Award to Advance its SASPject PT4 Aimed at Escherichia coli and Klebsiella pneumoniae Towards Clinical Trials
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer

List of Tables
  • Number of Products under Development for Klebsiella pneumoniae Infections, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Companies, 2022 (Contd..1)
  • Number of Products under Development by Companies, 2022 (Contd..2)
  • Number of Products under Development by Universities/Institutes, 2022
  • Products under Development by Companies, 2022
  • Products under Development by Companies, 2022 (Contd..1)
  • Products under Development by Companies, 2022 (Contd..2)
  • Products under Development by Companies, 2022 (Contd..3)
  • Products under Development by Universities/Institutes, 2022
  • Number of Products by Stage and Target, 2022
  • Number of Products by Stage and Mechanism of Action, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
  • Klebsiella pneumoniae Infections - Pipeline by ABAC Therapeutics SA, 2022
  • Klebsiella pneumoniae Infections - Pipeline by AEON Medix Inc, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Affinivax Inc, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Akthelia Pharmaceuticals Ltd, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Alterity Therapeutics Ltd, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Appili Therapeutics Inc, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Armata Pharmaceuticals Inc, 2022
  • Klebsiella pneumoniae Infections - Pipeline by BB200 LLC, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Bioversys AG, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Bugworks Research India Pvt Ltd, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Celdara Medical LLC, 2022
  • Klebsiella pneumoniae Infections - Pipeline by CHO Pharma Inc, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Clarametyx Biosciences Inc, 2022
  • Klebsiella pneumoniae Infections - Pipeline by ContraFect Corp, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Dong-A ST Co Ltd, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Entasis Therapeutics Holdings Inc, 2022
  • Klebsiella pneumoniae Infections - Pipeline by F. Hoffmann-La Roche Ltd, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Fedora Pharmaceuticals Inc, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Forge Therapeutics Inc, 2022
  • Klebsiella pneumoniae Infections - Pipeline by GSK plc, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Idorsia Pharmaceutical Ltd, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Infextious Therapeutic, 2022
  • Klebsiella pneumoniae Infections - Pipeline by LimmaTech Biologics AG, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Linnaeus Bioscience Inc, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Melinta Therapeutics Inc, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Microbiotix Inc, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Mikrobiomik Healthcare Company SL, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Nektr Technologies Ltd, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Neoculi Pty Ltd, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Nosopharm SAS, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Novabiotics Ltd, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Oryn Therapeutics, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Pedanius Therapeutics Ltd, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Peptilogics Inc, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Phico Therapeutics Ltd, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Planet Biotechnology Inc, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Recce Pharmaceuticals Ltd, 2022
  • Klebsiella pneumoniae Infections - Pipeline by RemAb Therapeutics SL, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Seres Therapeutics Inc, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Shionogi & Co Ltd, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Soligenix Inc, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Spero Therapeutics Inc, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Spexis AG, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Summit Therapeutics Inc, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Syntiron LLC, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Techulon Inc, 2022
  • Klebsiella pneumoniae Infections - Pipeline by VaxNewMO LLC, 2022
  • Klebsiella pneumoniae Infections - Pipeline by Venus Medicine Research Centre, 2022
  • Klebsiella pneumoniae Infections - Dormant Projects, 2022
  • Klebsiella pneumoniae Infections - Dormant Projects, 2022 (Contd..1)
  • Klebsiella pneumoniae Infections - Dormant Projects, 2022 (Contd..2)
  • Klebsiella pneumoniae Infections - Discontinued Products, 2022

List of Figures
  • Number of Products under Development for Klebsiella pneumoniae Infections, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Number of Products by Top 10 Targets, 2022
  • Number of Products by Stage and Top 10 Targets, 2022
  • Number of Products by Top 10 Mechanism of Actions, 2022
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2022
  • Number of Products by Routes of Administration, 2022
  • Number of Products by Stage and Routes of Administration, 2022
  • Number of Products by Top 10 Molecule Types, 2022
  • Number of Products by Stage and Top 10 Molecule Types, 2022

Companies Mentioned

A selection of companies mentioned in this report includes:

  • ABAC Therapeutics SA
  • AEON Medix Inc
  • Affinivax Inc
  • Akthelia Pharmaceuticals Ltd
  • Alterity Therapeutics Ltd
  • Appili Therapeutics Inc
  • Armata Pharmaceuticals Inc
  • BB200 LLC
  • Bioversys AG
  • Bugworks Research India Pvt Ltd
  • Celdara Medical LLC
  • CHO Pharma Inc
  • Clarametyx Biosciences Inc
  • ContraFect Corp
  • Dong-A ST Co Ltd
  • Entasis Therapeutics Holdings Inc
  • F. Hoffmann-La Roche Ltd
  • Fedora Pharmaceuticals Inc
  • Forge Therapeutics Inc
  • GSK plc
  • Idorsia Pharmaceutical Ltd
  • Infextious Therapeutic
  • LimmaTech Biologics AG
  • Linnaeus Bioscience Inc
  • Melinta Therapeutics Inc
  • Microbiotix Inc
  • Mikrobiomik Healthcare Company SL
  • Nektr Technologies Ltd
  • Neoculi Pty Ltd
  • Nosopharm SAS
  • Novabiotics Ltd
  • Oryn Therapeutics
  • Pedanius Therapeutics Ltd
  • Peptilogics Inc
  • Phico Therapeutics Ltd
  • Planet Biotechnology Inc
  • Recce Pharmaceuticals Ltd
  • RemAb Therapeutics SL
  • Seres Therapeutics Inc
  • Shionogi & Co Ltd
  • Soligenix Inc
  • Spero Therapeutics Inc
  • Spexis AG
  • Summit Therapeutics Inc
  • Syntiron LLC
  • Taisho Pharmaceutical Holdings Co Ltd
  • Techulon Inc
  • VaxNewMO LLC
  • Venus Medicine Research Centre